Abstracts tagged "DMARDs"

Abstract Number: 2646 • 2013 ACR/ARHP Annual Meeting
Cost-Effectiveness Analysis Of Triple Therapy Versus Etanercept Plus Methotrexate In Early Aggressive Rheumatoid Arthritis: Analysis Based On The TEAR Trial
Hawre Jalal¹, Jeffrey R. Curtis², Stacey Cofield³, Larry W. Moreland⁴, James R. O'Dell⁵ and Kaleb Michaud⁶, ¹Health Polisy and Management, University of Minnesota, Minneapolis, MN, ²Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵Veteran Affairs Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ⁶Rheumatology, National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The long-term cost-effectiveness of triple therapy (methotrexate [MTX], sulfasalazine [SSZ], hydroxychloroquine [HCQ]) disease modifying anti-rheumatic drugs (DMARDs) compared to a combination of MTX and…
Abstract Number: 1040 • 2013 ACR/ARHP Annual Meeting
Use Of TNF Inhibitors Is Associated With a Reduced Risk Of Diabetes In RA Patients
Siri Lillegraven¹, Jeffrey D. Greenberg², George W. Reed³, Katherine C. Saunders³, Jeffrey R. Curtis⁴, Leslie R. Harrold⁵, Marc C. Hochberg⁶, Dimitrios A. Pappas⁷, Joel M. Kremer⁸ and Daniel H. Solomon⁹, ¹Diakonhjemmet Hospital, Oslo, Norway, ²NYU Hospital for Joint Diseases, New York, NY, ³Corrona, LLC., Southborough, MA, ⁴Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵University of Massachusetts Medical School, Worcester, MA, ⁶Medicine, University of Maryland School of Medicine, Baltimore, MD, ⁷Department of Medicine, Division of Rheumatology, Columbia University, College of Physicians and Surgeons, New York, NY, ⁸Center for Rheumatology, Albany Medical College, Albany, NY, ⁹Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA
Background/Purpose: Inflammation may contribute to diabetes risk, and some studies indicate that certain DMARDs might be associated with a reduced risk of diabetes. Most studies…
Abstract Number: L14 • 2013 ACR/ARHP Annual Meeting
For Remission Induction with Glucocorticoid Bridging, Methotrexate Monotherapy Is As Effective As a Combination with Other Dmards, with Fewer Reported Side Effects: 4 Month Primary Outcome of Carera, a Randomized Induction Strategy and Treat to Target Trial in Early RA
Diederik De Cock¹, Sabrina Meyfroidt¹, Johan Joly², Kristien Van der Elst^2,3, Rene Westhovens^4,5 and Patrick Verschueren^2,6, ¹Skeletal Biology and Engineering Research Center, Department of Development and Regeneration, KU Leuven, Leuven, Belgium, ²University Hospitals Leuven on behalf of the CareRA Study Group, Leuven, Belgium, ³Skeletal Biology and Engineering Research Center, Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium, ⁴University of Leuven, Skeletal Biology and Engineering Research Center, Department of Development and Regeneration; Rheumatology, University Hospital Leuven, Leuven, Belgium, ⁵Skeletal Biology and Engineering Research Center, Department of Development and Regeneration, KU Leuven, Leuven, Belgium, KU Leuven, Leuven, Belgium, ⁶1Skeletal Biology and Engineering Research Center, Department of Development and Regeneration, KU Leuven, Leuven, Belgium
Background/Purpose: Intensive combination therapy with glucocorticoids (GCs) is the most favorable treatment to benefit from the window of opportunity in early Rheumatoid Arthritis (eRA) but…
Abstract Number: 2483 • 2013 ACR/ARHP Annual Meeting
Periarticular Bone Gain In Early Psoriatic Arthritis But Not In Rheumatoid Arthritis Following Anti-Rheumatic Treatment As Measured By Digital X-Ray Radiogrammetry
Agnes Szentpetery¹, Muhammad Haroon², Phil Gallagher³, Eric J. Heffernan⁴ and Oliver FitzGerald², ¹Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ²Department of Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ³Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, ⁴Radiology, St. Vincent's University Hospital, Dublin, Ireland
Background/Purpose: Hand bone loss is an early feature in both RA and PsA, but there is less data available on periarticular bone gain, in particular…
Abstract Number: 950 • 2013 ACR/ARHP Annual Meeting
Changes In Circulating Visfatin Levels By Different Anti-Rheumatic Treatments: A Comparison Among Synthetic Disease Modifying Anti-Rheumatic Drugs, Tumor Necrosis Factor Blockade and B-Cell Depletion For Rheumatoid Arthritis
Hana Hulejová¹, Markéta Kuklová², Herman F. Mann³, Mária Filková⁴, Olga Kryštufková⁵, Karel Pavelka⁶, Ondrej Sglunda⁷, Jiri Vencovsky⁸ and Ladislav Senolt⁸, ¹Department of Clinical and Experimental Rheumatology, 1st Faculty of Medicine, Charles University, Institute of Rheumatology, Prague, Czech Republic, ²Institute of Rheumatology, Department of Experimental Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, ³Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, ⁴Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, ⁵Institute of Rheumatology, and Dept. of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁶Department of Clinical and Experimental Rheumatology, Charles University, Prague, Czech Republic, ⁷Institute of Rheumatology and Department of Rheumatology of the First Faculty of Medicine, Charles University in Prague, Czech Republic, Prague, Czech Republic, ⁸Department of Clinical and Experimental Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Institute of Rheumatology, Prague, Czech Republic
Background/Purpose: Visfatin is an insulin mimetic adipokine that has been originally described as a pre-B cell colony-enhancing factor. Association between elevated visfatin levels, disease activity…
Abstract Number: 2334 • 2013 ACR/ARHP Annual Meeting
ORAL SCAN: Effects Of The Oral JAK Inhibitor Tofacitinib In Combination With Methotrexate On Patient Reported Outcomes In a 24-Month Phase 3 Trial Of Active Rheumatoid Arthritis
V. Strand¹, D. van der Heijde², C. a. F. Zerbini³, C. A. Connell⁴, D. Gruben⁴, R. Riese⁴ and G. Wallenstein⁴, ¹Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Rheumatology, Centro Paulista de Investigação Clinica, Sao Paulo, Brazil, ⁴Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Efficacy, inhibition of structural damage, and safety of tofacitinib…
Abstract Number: 833 • 2013 ACR/ARHP Annual Meeting
Cardiovascular Diseases In Rheumatoid Arthritis: Can Early Treatment With Disease-Modifying Antirheumatic Drugs Alter The Risk?
Rishi Desai¹, Jaya Rao², Richard Hansen³, Gang Fang⁴, Matthew Maciejewski⁵ and Joel Farley⁴, ¹Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, ²Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, ³Harrison School of Pharmacy, Auburn University, Auburn, AL, ⁴University of North Carolina, Chapel Hill, NC, ⁵Duke University, Durham, NC
Background/Purpose: Atherosclerosis is known to be accelerated in rheumatoid arthritis (RA) patients resulting in an increased cardiovascular (CV) risk. Structural damage to joints occurs aggressively…
Abstract Number: 2255 • 2013 ACR/ARHP Annual Meeting
Threshold Analysis of Patient Reported Morning Stiffness Where Delayed-Release (DR) Prednisone Was Compared to, and Replaced, Immediate Release Prednisone in Rheumatoid Arthritis (RA) Patients Receiving Conventional Disease-Modifying Antirheumatic Drugs (DMARDs) Over 1 Year
Frank Buttgereit¹, Jeffery Kent², Robert Holt², Amy Grahn³, Patricia Rice⁴, Rieke Alten⁵ and Yusuf Yazici⁶, ¹Charité - Universitätsmedizin Berlin, Berlin, Germany, ²Medical Affairs, Horizon Pharma, Inc, Deerfield, IL, ³Clinical Development, Horizon Pharma, Inc, Deerfield, IL, ⁴Statistics, CliniRx Research, Naperville, IL, ⁵Teaching Hospital of the Charité, University of Berlin, Berlin, Germany, ⁶New York University, New York, NY
Background/Purpose: RA patients typically present with pain and morning stiffness (MS) in addition to joint swelling and tenderness. Nocturnal inflammatory cytokines are assumed to be…
Abstract Number: 798 • 2013 ACR/ARHP Annual Meeting
Targeting Ultrasound Remission In Early Rheumatoid Arthritis – Results Of The Taser Study
James Dale¹, Anne Stirling², Iain B. McInnes¹ and Duncan Porter³, ¹Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Gartnavel General Hospital, Glasgow, United Kingdom, ³Rheumatology, Gartnavel General Hospital, Glasgow, United Kingdom
Background/Purpose: The TaSER study (NCT00920478) is an open label randomized clinical trial with blinded assessments of outcome. It was designed to test whether the efficacy…
Abstract Number: 2265 • 2013 ACR/ARHP Annual Meeting
Switching From Immediate Release (IR) Prednisone To Delayed Release (DR) Prednisone Improves Patient Reported Outcomes In Rheumatoid Arthritis (RA) Patients On Conventional Disease-Modifying Antirheumatic Drugs (DMARDs)
Rieke Alten¹, Robert Holt², Amy Grahn³, Patricia Rice⁴, Jeffery Kent², Frank Buttgereit⁵ and Allan Gibofsky⁶, ¹Teaching Hospital of the Charité, University of Berlin, Berlin, Germany, ²Medical Affairs, Horizon Pharma, Inc, Deerfield, IL, ³Clinical Development, Horizon Pharma, Inc, Deerfield, IL, ⁴Statistics, CliniRx Research, Naperville, IL, ⁵Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁶Medicine and Public Health, Hospital for Special Surgery, New York, NY
Background/Purpose: A surge in nocturnal inflammatory cytokines causing morning stiffness (MS) is recognized as a therapeutic target in RA. MS has been underappreciated in…
Abstract Number: 807 • 2013 ACR/ARHP Annual Meeting
Perioperative Use Of Anti-Rheumatic Agents Does Not Increase Early Postoperative Infection Risks: A Veteran Affairs’ Administrative Database Study
Zaki AbouZahr¹, Andrew Spiegelman², Maria Cantu³ and Bernard Ng⁴, ¹Baylor College of Medicine, Houston, TX, ²Michael E DeBakey Veteran Affairs Medical Center, Houston, TX, ³Baylor College Of Medicine, Houston, TX, ⁴Michael E. DeBakey VA Medical Center, Houston, TX
Background/Purpose: Evidences for perioperative management of disease modifying anti-rheumatic drugs (DMARDs) and biologic agents (BA) are sparse, and limited mainly to methotrexate & specific surgeries…
Abstract Number: 1913 • 2013 ACR/ARHP Annual Meeting
Expectations RA Patients Have For Their Treatment – A Comparison Of Clinical Results For Biologic and Disease-Modifying Anti-Rheumatic Drug Treated Patients Using Multiple Medical Cohorts
Tsukasa Matsubara^1,2, Hiroaki Matsuno², Tomomaro Izumihara², Yuichi Takahashi², Akira Sagawa², Motohiro Oribe², Eisuke Shono², Kensuke Kume², Masanori Adachi², Yuichi Nishioka², Nobumasa Miyake², Keisuke Hashimoto², Toshikaki Miyamoto², Shigeto Kiyokawa², Tomohiko Yoshida², Syoichi Kondo², Yoshiki Shiohira², Takanori Azuma², Yukio Sato², Masaaki Yoshida², Kenji Mannami², Akihiko Nakamura², Yasuhiko Hirabarashi², Keiko Funahashi³ and James E. Middleton⁴, ¹Department of Orthopedics, Matsubara Mayflower Hospital, Kato, Japan, ²Japanese Clinician's Biologic Research Group, Kobe, Japan, ³Department of Clinical Research, Matsubara Mayflower Hospital, Kato, Japan, ⁴Research Institute of Joint Diseases, Kobe, Japan
Background/Purpose: Treat to Target (T2T) primary principal - “The treatment of rheumatoid arthritis must be based on a shared decision between patient and rheumatologist”. Japan…
Abstract Number: 480 • 2013 ACR/ARHP Annual Meeting
Levels Of Circulating Mirnas Before and After 12 Months Therapy With Dmards In Patients With Early Rheumatoid Arthritis
Mária Filková¹, Borbala Aradi², Ladislav Senolt³, Klara Prajzlerova⁴, Serena Vettori², Herman F. Mann⁵, Jiri Vencovsky⁴, K. Pavelka⁶, Beat A. Michel⁷, Renate E Gay², Steffen Gay² and Astrid Jüngel², ¹Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, ²Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP), Zurich, Switzerland, ³Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁴Institute of Rheumatology, Department of Clinical and Experimental Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁵Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, ⁶Department of Clinical and Experimental Rheumatology, Charles University, Prague, Czech Republic, ⁷Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: The altered expression of cellular miRNAs in the immune and resident cells involved in the pathogenesis of rheumatoid arthritis (RA) has been shown to…
Abstract Number: 1843 • 2013 ACR/ARHP Annual Meeting
Treatment With Staphyloccocal Protein A Which Is Immuno-Modulatory In The Murine Collagen Arthritis Model, Does Not Increase Infection Severity In Murine Listeria Or Candida Challenge Models, In Contrast To Anti-TNF Treatment
Edward Bernton¹ and Valerie Lowe², ¹Protalex Inc., Summit, NJ, ²Washington Biotechnology, Inc., Baltimore, MD
Background/Purpose: PRTX-100 is a highly-purified GMP staphylococcal protein A (SpA) that is currently in Phase I trials in patients with active rheumatoid arthritis (RA). SpA…
Abstract Number: 489 • 2013 ACR/ARHP Annual Meeting
Combining Methotrexate To Etanercept Does Not Improve Its Retention Rate In Rheumatoid Arthritis Patients When Compared To Etanercept Monotherapy. A Report From The Rhumadata® Clinical Data Base and Registry
Denis Choquette¹, Louis Bessette², Boulos Haraoui¹, Diane Sauvageau³, Jean Pierre Pelletier¹, Jean-Pierre Raynauld³, Edith Villeneuve³ and Louis Coupal¹, ¹Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ²Centre Hospitalier Universitaire de Québec, pavillon CHUL, Sainte-Foy, QC, Canada, ³Rheumatology, Institut de Rhumatologie de Montréal, Montreal, QC, Canada
Background/Purpose: Etanercept (ETA) has demonstrated good retention in both mono and combination therapy in clinical trials of rheumatoid arthritis patients followed over short observation periods…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.